Denise M Ney1, Sangita G Murali2, Bridget M Stroup2, Nivedita Nair2, Emily A Sawin2, Fran Rohr3, Harvey L Levy3. 1. Department of Nutritional Sciences, University of Wisconsin-Madison, WI, United States. Electronic address: ney@nutrisci.wisc.edu. 2. Department of Nutritional Sciences, University of Wisconsin-Madison, WI, United States. 3. Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.
Abstract
BACKGROUND: Deficiencies of the monoamine neurotransmitters, such as dopamine synthesized from Tyr and serotonin synthesized from Trp, are of concern in PKU. Our objective was to utilize metabolomics analysis to assess monoamine metabolites in subjects with PKU consuming amino acid medical foods (AA-MF) and glycomacropeptide medical foods (GMP-MF). METHODS: Subjects with PKU consumed a low-Phe diet combined with AA-MF or GMP-MF for 3weeks each in a randomized, controlled, crossover study. Metabolomic analysis was conducted by Metabolon, Inc. on plasma (n=18) and urine (n=9) samples. Catecholamines and 6-sulfatoxymelatonin were measured in 24-h urine samples. RESULTS: Intake of Tyr and Trp was ~50% higher with AA-MF, and AA-MF were consumed in larger quantities, less frequently during the day compared with GMP-MF. Performance on neuropsychological tests and concentrations of neurotransmitters derived from Tyr and Trp were not significantly different with AA-MF or GMP-MF. Plasma serotonin levels of gut origin were higher in subjects with variant compared with classical PKU, and with GMP-MF compared with AA-MF in subjects with variant PKU. Metabolomics analysis identified higher levels of microbiome-derived compounds synthesized from Tyr, such as phenol sulfate, and higher levels of compounds synthesized from Trp in the kynurenine pathway, such as quinolinic acid, with ingestion of AA-MF compared with GMP-MF. CONCLUSIONS: The Tyr from AA-MF is less bioavailable due, in part, to greater degradation by intestinal microbes compared with the Tyr from prebiotic GMP-MF. Research is needed to understand how metabolism of Trp via the kynurenine pathway and changes in the intestinal microbiota affect health for individuals with PKU. This trial is registered at www.clinicaltrials.gov as NCT01428258.
RCT Entities:
BACKGROUND: Deficiencies of the monoamine neurotransmitters, such as dopamine synthesized from Tyr and serotonin synthesized from Trp, are of concern in PKU. Our objective was to utilize metabolomics analysis to assess monoamine metabolites in subjects with PKU consuming amino acid medical foods (AA-MF) and glycomacropeptide medical foods (GMP-MF). METHODS: Subjects with PKU consumed a low-Phe diet combined with AA-MF or GMP-MF for 3weeks each in a randomized, controlled, crossover study. Metabolomic analysis was conducted by Metabolon, Inc. on plasma (n=18) and urine (n=9) samples. Catecholamines and 6-sulfatoxymelatonin were measured in 24-h urine samples. RESULTS: Intake of Tyr and Trp was ~50% higher with AA-MF, and AA-MF were consumed in larger quantities, less frequently during the day compared with GMP-MF. Performance on neuropsychological tests and concentrations of neurotransmitters derived from Tyr and Trp were not significantly different with AA-MF or GMP-MF. Plasma serotonin levels of gut origin were higher in subjects with variant compared with classical PKU, and with GMP-MF compared with AA-MF in subjects with variant PKU. Metabolomics analysis identified higher levels of microbiome-derived compounds synthesized from Tyr, such as phenol sulfate, and higher levels of compounds synthesized from Trp in the kynurenine pathway, such as quinolinic acid, with ingestion of AA-MF compared with GMP-MF. CONCLUSIONS: The Tyr from AA-MF is less bioavailable due, in part, to greater degradation by intestinal microbes compared with the Tyr from prebiotic GMP-MF. Research is needed to understand how metabolism of Trp via the kynurenine pathway and changes in the intestinal microbiota affect health for individuals with PKU. This trial is registered at www.clinicaltrials.gov as NCT01428258.
Authors: William R Wikoff; Andrew T Anfora; Jun Liu; Peter G Schultz; Scott A Lesley; Eric C Peters; Gary Siuzdak Journal: Proc Natl Acad Sci U S A Date: 2009-02-20 Impact factor: 11.205
Authors: Ann W Hsing; Tamra E Meyer; Shelley Niwa; Sabah M Quraishi; Lisa W Chu Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Sandra C van Calcar; Erin L MacLeod; Sally T Gleason; Mark R Etzel; Murray K Clayton; Jon A Wolff; Denise M Ney Journal: Am J Clin Nutr Date: 2009-02-25 Impact factor: 7.045
Authors: Bridget M Stroup; Nivedita Nair; Sangita G Murali; Katarzyna Broniowska; Fran Rohr; Harvey L Levy; Denise M Ney Journal: J Nutr Date: 2018-02-01 Impact factor: 4.798
Authors: Bridget M Stroup; Denise M Ney; Sangita G Murali; Frances Rohr; Sally T Gleason; Sandra C van Calcar; Harvey L Levy Journal: J Nutr Metab Date: 2017-12-31
Authors: Els van der Goot; Francjan J van Spronsen; Joana Falcão Salles; Eddy A van der Zee Journal: Front Endocrinol (Lausanne) Date: 2020-09-02 Impact factor: 5.555